MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells

Funamizu,Naotake; Lacy,Curtis Ray; Parpart,Sonya T.; Takai,Atsushi; Hiyoshi,Yukiharu; Yanaga,Katsuhiko

doi:10.3892/ijo.2014.2243

MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells

Authors:
- Naotake Funamizu
- Curtis Ray Lacy
- Sonya T. Parpart
- Atsushi Takai
- Yukiharu Hiyoshi
- Katsuhiko Yanaga
View Affiliations

Affiliations: Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan, Howard University School of Medicine, Washington DC, USA, Georgetown University, Washington DC, USA, Department of Gastroenterology, Kyoto University, Kyoto, Japan, Department of Surgery, Kumamoto University, Kumamoto, Japan
Published online on: January 7, 2014 https://doi.org/10.3892/ijo.2014.2243
Pages: 725-734

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have demonstrated that deregulated microRNA (miR) expression is implicated in the development of human cancers. In the aberrant miR expression, miR-301 is upregulated in cancers, such as pancreatic, colorectal and oral carcinoma. Based on this evidence, we investigated the contribution of miR-301 to pancreatic carcinoma and the novel target genes of miR-301 in pancreatic carcinoma. In this study, we analyzed the effects of enforced and inhibited expression of miR-301b expression in the Panc-1 and BxPC-3 cell lines. MiR-301b expression levels were associated with cell invasiveness in both cell lines. Additional experiments indicated that miR-301b influences invasiveness through CDH1. Moreover microRNA target search algorithms and experimental strategies suggested that miR-301b suppressed TP63 expression as a novel target of miR-301b. Remarkably, miR-301b was also found to be associated with NF-κB activity in both cell lines. In summary, overexpressed miR-301b may suppress TP63 expression and contributes to promote cell invasiveness and to enhance gemcitabine resistance in pancreatic carcinoma cells. Thus, miR-301b may have potential as a novel therapeutic target for cancer treatment due to its stimulatory effects on cell invasiveness.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2.	Eltawil KM, Renfrew PD and Molinari M: Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB (Oxford). 14:260–268. 2012. View Article : Google Scholar : PubMed/NCBI
3.	Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
4.	Bartel D: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, et al: MiRNA expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One. 7:e336632012. View Article : Google Scholar : PubMed/NCBI
6.	Nikitina EG, Urazova LN and Stegny VN: MicroRNAs and human cancer. Exp Oncol. 34:2–8. 2012.
7.	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
8.	Li C, Hashimi SM, Good DA, Cao S, Duam W, et al: Apoptosis and microRNA aberrations in cancer. Clin Exp Pharmacol Physiol. 39:739–746. 2012. View Article : Google Scholar : PubMed/NCBI
9.	Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, et al: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 18:74–82. 2011.PubMed/NCBI
10.	Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, et al: A miR-200b/200c/429-binding site polymorphism in the 3′ untranslated region of the AP-2α gene is associated with cisplatin resistance. PLoS One. 6:e290432011.PubMed/NCBI
11.	Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, et al: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, et al: Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 14:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Miko E, Czimmerer Z, Csánky E, Boros G, Buslig J, et al: Differentially expressed microRNAs in small cell lung cancer. Exp Lung Res. 35:646–664. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Lu YC, Chen YJ, Wang HM, Tsai CY, Chen WH, et al: Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res. 5:665–674. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM and Gao HJ: Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 11:50–54. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Cao G, Huang B, Liu Z, Zhang J, Xu H, et al: Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting MEOX2 to affect ERK/CREB pathways. Biochem Biophys Res Commun. 396:978–982. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, et al: MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Lu Z, Li Y, Takwi A, Li B, Zhang J, et al: miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J. 30:57–67. 2011.
19.	Funamizu N, Okamoto A, Kamata Y, Misawa T, Uwagawa T, et al: Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase? Oncol Rep. 23:471–475. 2010.PubMed/NCBI
20.	Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, et al: p63, a p53 homolog at 3q27-29, encodes multiple products with trans-activating, death-inducing, and dominant-negative activities. Mol Cell. 2:305–316. 1998. View Article : Google Scholar : PubMed/NCBI
21.	Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, et al: p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 398:714–718. 1999. View Article : Google Scholar : PubMed/NCBI
22.	Yuan M, Luong P, Hudson C, Gudmundsdottir K and Basu S: c-Abl phosphorylation of ΔNp63α is critical for cell viability. Cell Death Dis. 1:e162010.
23.	Helton ES, Zhang J and Chen X: The proline-rich domain in p63 is necessary for the transcriptional and apoptosis-inducing activities of TAp63. Oncogene. 27:2843–2850. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, et al: TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 24:2458–2471. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, et al: TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol. 11:1451–1457. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Chiang CT, Chu WK, Chow SE and Chen JK: Overexpression of delta Np63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation. J Cell Physiol. 219:117–122. 2009. View Article : Google Scholar : PubMed/NCBI
27.	Schavolt KL and Pietenpol JA: p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis. Oncogene. 26:6125–6132. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Sen T, Sen N, Huang Y, Sinha D, Luo ZG, et al: Tumor protein p63/nuclear factor κB feedback loop in regulation of cell death. J Biol Chem. 286:43204–43213. 2011.PubMed/NCBI
29.	Wu J, Bergholz J, Lu J, Sonenshein GE and Xiao ZX: TAp63 is a transcriptional target of NF-kappaB. J Cell Biochem. 109:702–710. 2010.PubMed/NCBI
30.	Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
31.	Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S and Nakshatri H: NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene. 26:711–724. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Funamizu N, Kamata Y, Misawa T, Uwagawa T, Lacy CR, et al: Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase. Pancreas. 41:107–113. 2010. View Article : Google Scholar
33.	Funamizu N, Lacy CR, Fujita K, Furukawa K, Takeyuki M, et al: Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 7:e374242012. View Article : Google Scholar : PubMed/NCBI